drugset / Trial / NCT03951077
Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome
RandomizedParallel-groupTriple-blindTreatment
Summary
This study will assess the potential impact of elagolix on disordered pituitary and ovarian hormones in women with polycystic ovary syndrome (PCOS).
Timeline
- Start
- 2019-08-12
- Primary completion
- 2021-02-10
- Completion
- 2021-02-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elagolix | Small molecule | 25 mg | Oral |
| Subject | Elagolix | Small molecule | 50 mg | Oral |
| Subject | Elagolix | Small molecule | 75 mg | Oral |
| Subject | Elagolix | Small molecule | 150 mg | Oral |
| Subject | Elagolix | Small molecule | 300 mg | Oral |